ROOLIFE GROUP LIMITED (ASX: RLG) (RooLife
Group or “Company”) has ANNOUNCED that the Company
has partnered with AFT Pharmaceuticals (ASX: AFP) to launch over-the-counter
(OTC) pharmaceuticals in China. The OTC medications will be sold through the
Kiwi Health Global Flagship store on Tmall Global, an online platform.
The store is registered under the Chinese
cross-border e-commerce (CBEC) OTC pilot scheme. Under the scheme, this is the
first New Zealand direct to consumer OTC marketplace in China. The launch will
be completed over two phases, and the product portfolio will be expanded to
include AFT Pharmaceuticals’ patented pain relief medication Maxigesic and five
other OTC products.
RooLife
Group’s Role
ROOLIFE GROUP will oversee digital marketing and
store operation of the store. The Company will also ensure the sale of AFT
Pharmaceuticals’ products including vitamin C and D lipo sachets, Loraclear hay
fever relief, Ferro sachets, Kiwisoothe, Histaclear non-drowsy allergy relief,
and Crystalwash Extend. In addition, RooLife Group will also be responsible for
the end-to-end approval process to ensure AFT Pharmaceuticals can sell its OTC
products in China.
Commenting on the partnership,
RooLife MANAGING DIRECTOR BRYAN CARR said,
“The partnership with AFT Pharmaceuticals puts us at the forefront. We can
directly service the strong demand for international OTC products from Chinese
consumers. Since the partnership leverages our experience in Chinese e-commerce
and market and AFT Pharmaceuticals’ pharmaceutical experience, it represents an
excellent achievement for both.”
Comments
Post a Comment